Mizuho Maintains Neutral on Corvus Pharma, Maintains $3.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Corvus Pharma (NASDAQ:CRVS) and keeps the price target at $3.5.

March 27, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho maintains a Neutral rating on Corvus Pharma with a $3.5 price target.
The maintenance of a Neutral rating and a $3.5 price target by Mizuho suggests no significant short-term price movement is expected for Corvus Pharma. The analyst's view likely reflects a balanced outlook on the company's prospects, without strong indicators for either positive or negative performance in the near term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90